By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Vertex Pharmaceuticals Incorporated 

130 Waverly Street

Cambridge  Massachusetts  02139-4242  U.S.A.
Phone: 617-444-6100 Fax: 617-444-6680


SEARCH JOBS




The Science of Possibility.

The first thing you’ll notice about Vertex is that we are not a conventional pharmaceutical company. Each and every person at Vertex is driven by a passion for fearless innovation and a bold desire to transform the lives of millions with new medicines. Together, by creating new possibilities in medicine, our employees are quite literally changing the world.

Vertex scientists and our collaborators are working on new medicines to advance the treatment of hepatitis C, cystic fibrosis, rheumatoid arthritis and other life-threatening diseases. Our development pipeline includes several investigational drugs that have the potential to transform the treatment of serious diseases. Every day brings us a step closer to getting patients the medicines they need and potentially changing their lives in previously unimaginable ways. It’s a demanding yet incredibly rewarding experience that cannot help but change your life in the process, too.

We employ more than 2,000 of the industry’s best and brightest people at locations around the world – all of us working toward tomorrow’s breakthrough medicines.

For more information on Vertex, please visit www.vrtx.com. For information on career opportunities with Vertex, please visit www.careers.vrtx.com..

Key Contacts:
Media: mediainfo@vrtx.com
Investors: investorinfo@vrtx.com
Patient Inquiries: clinical_trials@vrtx.com


This div will be replaced


Key Statistics


Email:
Ownership: Public

Web Site: Vertex Pharmaceuticals (MA)
Employees: ~1000
Symbol: VRTX
 





Collaborations

Cystic Fibrosis Foundation Therapeutics, Inc.  (VX-770 for CF)

Kissei Pharmaceutical Co., Ltd.  (VX-702 for RA)

GlaxoSmithKline  (VX-409 and Backup Compounds)

Janssen Pharmaceutica N.V.  (telaprevir for HCV) - Europe, South America, Australia, the Middle East and other countries

Merck & Co., Inc.  (MK-0457 (VX-680), MK-6592 (VX-667) and VX-689 for Cancer)

Mitsubishi Pharma Corporation  (telaprevir for HCV) - Japan and certain Far East countries





Company News
Vertex Pharmaceuticals (MA) (VRTX) To Announce Second Quarter 2014 Financial Results On July 29 7/15/2014 10:09:07 AM
Vertex Pharmaceuticals (MA) (VRTX) Announces Retirement Of Peter Mueller, Ph.D. 7/10/2014 11:19:15 AM
Vertex Pharmaceuticals (MA) (VRTX) Submits Supplemental New Drug Application (sNDA) To FDA For Use Of KALYDECO® (Ivacaftor) In People 18 And Older With Cystic Fibrosis Who Have The R117H Mutation 7/1/2014 11:06:08 AM
Vertex Pharmaceuticals (MA) (VRTX) Grabs EU Recommendation For KALYDECO™ (Ivacaftor) In Eight Non-G551D Gating Mutations 6/27/2014 6:20:08 AM
Vertex Pharmaceuticals (MA) (VRTX) Rockets As Cystic Fibrosis Combo Succeeds In Two Late Stage Trials 6/24/2014 6:29:44 AM
Johnson & Johnson (JNJ)'s Janssen Pharmaceutical Inc. Strikes Influenza A Deal With Vertex Pharmaceuticals (MA) (VRTX) 6/18/2014 7:12:44 AM
Vertex Pharmaceuticals (MA) (VRTX) Announces A Signed Letter Of Intent To Enable Public Reimbursement Of KALYDECO® (Ivacaftor) In Canada For Eligible People With Cystic Fibrosis 6/17/2014 11:37:38 AM
Analyst Makes A Trip To Sweden, Returns Home Predicting Vertex Pharmaceuticals (MA) (VRTX) Cystic Fibrosis Drug Failure 6/17/2014 6:36:13 AM
Vertex Pharmaceuticals (MA) (VRTX) Announces Presentation Of New KALYDECO™ (Ivacaftor) Data At European Cystic Fibrosis Society Conference 6/12/2014 8:15:28 AM
Vertex Pharmaceuticals (MA) (VRTX) Trial Suggests Kalydeco May Work In More Cystic Fibrosis Patients 6/5/2014 9:46:50 AM
12345678910...
//-->